Speaker Profile
SVP BioPharma Business Development, Adaptive Biotech
Biography
Mary Pat Lancelotta is currently the Senior Vice President of the BioPharma business at Adaptive Biotechnologies, a commercial-stage biotech company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease. Mary Pat brings over 20 years of commercial and strategy experience in life sciences and diagnostics with a strong focus in oncology, and she has held leadership roles in both start-ups and Fortune 500 companies. She previously served as Vice President Strategic Marketing at Foundation Medicine where she launched FoundationOne and FoundationOne Heme and led strategic communications through several rounds of financing, including the IPO and acquisition by Roche. She came to FMI from Quest Diagnostics where she led commercial strategy for the company’s $5B laboratory services business and served as chief-of-staff to the Chief Medical Officer. Mary Pat also spent seven years in consulting with Accenture and The Frankel Group, a boutique life sciences consulting firm. Mary Pat has also served as a strategic consultant to several early stage oncology/early detection diagnostic companies. She also serves/has served on the board of directors for two private companies, Molecular Match and Ultivue, as well as a non-profit advancing clinical research for rare cancers, Target Cancer Foundation. Mary Pat holds an MBA with honors from Columbia Business School and a BS in Biochemistry, magna cum laude, from Boston College.
Session Abstract – PMWC 2024 Silicon Valley
Track Chair: Laura J. van 't Veer, UCSF
- PMWC 2024 Award Ceremony
Pioneer Honoree: David Sidransky, Johns Hopkins
Pioneer Honoree: Helmy Eltoukhy
Pioneer Honoree: AmirAli Talasaz, Guardant Health - Utilities of Liquid Biopsy in Biomarker Testing
- Laura Vent Veer, UCSF - Status Quo of Clinical Liquid Biopsy (PANEL)
Chair: Helmy Eltoukhy, Guardant Health
- Sadakatsu Ikeda, Tokyo Medical University
- Heather Parsons, Dana-Farber Cancer Institute
- Sanjay Popat, The Royal Marsden - Liquid Biopsy for Health Monitoring and Disease Prevention (PANEL)
Chair: Anne-Renee Hartman, Adela Bio
- AmirAli Talasaz, Guardant Health
- Heather Parsons, Dana-Farber Cancer Institute
- Mary Pat Lancelotta, Adaptive Bio
- Sylvia Katina Plevritis, Stanford - Multi-Cancer Early Detection Through Multi-Biomarker Class Liquid Biopsy Testing (PANEL)
Chair: Tom Beer, Exact Sciences
- Wendy Rubinstein, National Cancer Institute
- Sheila D. Walcoff, Goldbug Strategies LLC - Keynote: Pioneering Liquid Nucleic Acids Tumor Fragments in Health and Diseases
- David Sidransky, Johns Hopkins - New Approaches in Liquid Biopsy (PANEL)
Chair: Victor Velculescu, Johns Hopkins
- David Sidransky, Johns Hopkins
- Dan Laudau, NY Genome Center
- Daniel De Carvalho, University of Toronto - Global Implications: A scalable Liquid Biopsy for HPV-related Cervical Cancer (PANEL)
Chair: Debra Fraser-Howze, D. Fraser Associates
- Belinda Nedjai, Wolfson Institute of Population Health
- Elisabeth Adams, Aquarius Population Health Limited - NCI Showcase
- Xiaohui Ni, Early Dx
- Daniel Kim, UCSC
